Artemisin

Summary

Artemisin (CHEMBL77) is a phase-3 clinical-stage small molecule; indicated across 1 condition including malaria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 282.33 Da · C15H22O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL77
Name	Artemisin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	44266427
Molecular formula	C15H22O5
Molecular weight	282.33
InChIKey	BLUAFEHZUWYNDE-XRNKLDBLSA-N

SMILES: C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3C24[C@H]1CC[C@@](O3)(OO4)C)C

IUPAC name: (1S,4S,5R,8S,9R,12S)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one

Also known as: Artemisin, SID50109945, SID144205303, ARTEMISIN

Patent coverage: 36 distinct patent families (61 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Huntingtin.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTT	5.5	Potency	3162	nM	CHEMBL_ACT_3759125

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
malaria	3	MONDO:0005136	EFO:0001068

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).